Strategy for enhancing immune cell infiltration could be combined with other methods to improve cell-based immunotherapies ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Cancer immunotherapy has been revolutionized by targeting specific immune subsets within the tumor microenvironment, where T cells play a pivotal role. Gene-engineered T cell strategies and immune ...

Alicia Zhou, PhD, became CRI’s president effective August 26, and succeeded Jill O’Donnell-Tormey, PhD, who had led the Institute since 1993.

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells-;a type of cancer immunotherapy-;that can be switched on to varying degrees of intensity and then ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...